Click the HTML icon in the toolbar above to edit spacer height.
TO EDIT: Change the class="spacer-3" to any number between 0 (none) and 5 (most) to resize a spacer. Ex. class="spacer-5"
Vertical spacers are responsive and 50% smaller on mobile than on tablet+.

Comprehensive off-target analysis for your CRISPR project, from research to clinical applications

Get a free consultation from one of our CRISPR experts


Click the HTML icon in the toolbar above to edit spacer height.
TO EDIT: Change the class="spacer-3" to any number between 0 (none) and 5 (most) to resize a spacer. Ex. class="spacer-5"
Vertical spacers are responsive and 50% smaller on mobile than on tablet+.
IDT, a global leader in CRISPR genome editing solutions,  and SeQure Dx, experts in off-target analysis, have joined forces to deliver unparalleled off-target editing analytical services for your CRISPR projects from research to clinic.

This licensing agreement merges best-in-class technology with end-to-end development solutions, ensuring a seamless and efficient therapeutic development process.

Why choose our comprehensive OTE analysis services?
  1. Integrated solutions: The licensing agreement provides a one-stop solution for all phases of CRISPR therapeutic development, combining SeQure Dx’s next-generation sequencing-based gene editing off-target analysis technology, GUIDE-seq. with IDT’s RUO-to-CGMP complete workflow, including the award-winning rhAmpSeq™ CRISPR Analysis System.
  2. Streamlined process: Work with a single provider throughout your journey, reducing the risk of errors and delays.
  3. Regulatory support aligned with pre-clinical, clinical and commercialization phases: IDT is prepared to support you with the required information tailored to your unique needs based on use, clinical program phase, and modality. Navigate regulatory requirements with confidence.
  4. Dedicated expert team: Your project is in the hands of a dedicated, cross-functional team at IDT. Each team member is an expert in their field, working diligently to ensure the success of your CRISPR program from research to clinic.
Let’s take your CRISPR therapeutics research into the clinic!

Start the conversation today to learn more about our advanced OTE analysis services.

Rapidly move  from the lab to therapeutic clinical trials. We’ll help.
Click the HTML icon in the toolbar above to edit spacer height.
TO EDIT: Change the class="spacer-3" to any number between 0 (none) and 5 (most) to resize a spacer. Ex. class="spacer-5"
Vertical spacers are responsive and 50% smaller on mobile than on tablet+.
Click the HTML icon in the toolbar above to edit spacer height.
TO EDIT: Change the class="spacer-3" to any number between 0 (none) and 5 (most) to resize a spacer. Ex. class="spacer-5"
Vertical spacers are responsive and 50% smaller on mobile than on tablet+.
24-GE-LP-SeQure-Dx-Partnership-sandy-ottensmann.png

“At IDT, we are committed to advancing the field of CRISPR therapeutics by providing our customers with the most comprehensive and reliable solutions. Our partnership with SeQure Dx enables us to deliver off-target editing analytical services that streamline the entire development process, from research to clinical applications.”  

—Sandy Ottensmann, IDT Vice President and General Manager of Gene Writing and Editing

24-GE-LP-SeQure-Dx-Partnership-Keith-Young.png

“SeQure's best-in-class off-target nomination and confirmation platforms will seamlessly complement IDT’s CRISPR-based portfolio of products and services. Combining SeQure’s and IDT’s innovative technologies will enhance precision and safety in gene editing, bringing transformative solutions to researchers and patients worldwide.”

—Keith Joung, SeQure Dx Scientific Founder